Diagnosis & Disease Information

How many of your patients need compounded drugs?

FDA Approves Label Update for Abiraterone

The FDA has approved a label update for abiraterone acetate (Zytiga) to include data showing that the drug is associated with significantly prolonged overall survival compared with placebo plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer. The data, published recently in The Lancet Oncology (online ahead of print), showed that abiraterone treatment prolonged…

Next post in Bladder Cancer